CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Pharmaceutical giant GlaxoSmithKline is sidestepping its pledge to lower asthma inhaler prices, a key senator charged Wednesday, in the latest effort by Democrats to pressure drug companies on the ...

24 Jul, 2018 11 Sep, 2018 1:1 For every 1 share held; Holder will receive 1 bonus shares. 28 Sep, 1994 02 Jan, 1995 1:1 For every 1 share held; Holder will receive 1 bonus shares. 23 Jun, 1980-1:3 ...

GlaxoSmithKline is improving process efficiency in the production of pharmaceutical powders at its ‘centre of excellence’ plant in Dartford, ...

At GlaxoSmithKline, we never lose sight of the fact that patients are at the core of what we do and that millions of lives are impacted by cancer. The patient’s voice is at the heart of our ...

Pharmaceuticals giant GlaxoSmithKline ( GSK.L) (GSK) has lifted its long-term sales guidance as it hailed a strong drugs ...

Explore the detailed Glaxo Smith Kline balance sheet to understand the company’s financial health and stability. This page provides a clear breakdown of key metrics, including total assets ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...